Features and properties

Limits...

Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101. - Drugs R D (2010) Bottom Line: Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections.It is currently in phase III development with promising results so far.This review looks at the development history and scientific profile of this drug to date. View Article: PubMed Central - PubMed ABSTRACT Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date. Show MeSH Major Aminoglycosides/pharmacology/therapeutic use Anti-Bacterial Agents/pharmacology/therapeutic use* Clostridium Infections/drug therapy* Minor Animals Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic DNA-Directed RNA Polymerases/antagonists & inhibitors Drugs, Investigational/pharmacology/therapeutic use Humans Microbial Sensitivity Tests Related in: MedlinePlus	© Copyright Policy Related In: Results - Collection Show All Figures getmorefigures.php?uid=PMC3585687&req=5 Tab1: Features and properties

Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.

- Drugs R D (2010)

Bottom Line: Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections.It is currently in phase III development with promising results so far.This review looks at the development history and scientific profile of this drug to date.

View Article: PubMed Central - PubMed

ABSTRACT

Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date.